Outro

Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

0

0

0 Visualizações· 09/04/23

OncLive® On Air
0 Assinantes

Dentro

Dr Usmani discusses the integration of elranatamab, talquetamab, and telcistamab into the management of relapsed/refractory multiple myeloma, common adverse effects and recommended supportive care measures, and ongoing research that may help clarify their role in the paradigm.

Mostre mais

0 Comentários

A seguir

Reprodução automática

Casa

Explore mais

Ajuda